Amendments to Claims

Claims 1-43 (Canceled).

44. (Currently amended) A method of recovering stable Factor VIII/ von Willebrand Factor (vWF)-complex from a protein solution ~~that also contains contaminating~~ contaminated with other proteins, wherein the method comprises

binding the Factor VIII/vWF-complex contained in the protein solution to an anion exchanger;

selectively eluting the ~~contaminating~~ other proteins with an eluting agent containing a calcium salt and an elution salt, wherein the elution salt is present at a concentration of no more than 200 mM ~~and and a calcium salt~~, and

subsequently recovering Factor VIII/vWF-complex from the anion exchanger ~~in the absence of calcium at~~ using a buffer having an elution salt at a concentration of 200 to 400 mM, wherein the buffer is without a calcium salt.

45. (Currently amended) The method according to claim ~~44~~, wherein the ~~contaminating~~ other proteins are plasma proteins.

46. (Previously presented) The method according to claim 45, wherein the plasma proteins are selected from the group consisting of Vitamin K-dependent Factors, plasma proteases, fibronectin and fibrinogen.

47. (Previously presented) The method according to claim 44, wherein the calcium salt is $CaCl_2$ and is contained in the eluting agent at a concentration of 1 mM to 15 mM.

48. (Previously presented) The method according to claim 47, wherein the $CaCl_2$ is contained in the eluting agent at a concentration of 10 mM.

49. (Previously presented) The method according to claim 44, wherein the eluting is carried out at a pH of 6.0 to 8.5.

50. (Previously presented) The method according to claim 44, wherein the eluting is carried out at a pH of 7.4.

51. (Previously presented) The method according to claim 44, wherein the elution salt contained in the eluting agent is NaCl.

52. (Previously presented) The method according to claim 44, wherein a Factor VIII/vWF-complex containing high-molecular vWF multimers is obtained, and the Factor VIII/vWF-complex is free from low-molecular vWF molecules and from vWF degradation products.

53. (Previously presented) The method according to claim 44, further comprising subjecting the Factor VIII/vWF-complex recovered from said anion exchanger to a further chromatographic step.

54. (Previously presented) The method according to claim 53, wherein the further chromatographic step is affinity chromatography.

55. (Previously presented) The method according to claim 54, wherein the affinity chromatography is heparin chromatography carried out with a heparin affinity carrier by binding the Factor VIII/vWF-complex from the protein solution to the heparin affinity carrier in a buffer system and recovering the Factor VIII/vWF-complex at an elution salt concentration of 200 to 300 mM.

56. (Currently amended) The method according to claim 55, wherein the heparin affinity carrier is selected from the group consisting of AF- ~~Heparin Toyopearl~~ HEPARIN TOYOPEARL® (synthetic, hydrophilic polymer of large pore size based on methacrylate), ~~Heparin EMD-Fractogel~~ HEPARIN EMD-FRACTOGEL® (synthetic, hydrophilic polymer based on ethylene glycol, methacrylate and dimethyl acrylate) and ~~Heparin Sepharose Fast Flow~~ HEPARIN-SEPHAROSE FAST FLOW® (containing natural dextran and agarose derivatives).

Claims 57-63 (Canceled).